BRAF and colorectal carcinoma: In a recent meta-analysis of 149 articles, among patients with EO-CRC, there is a higher prevalence of mutations in several oncogenes linked to mortality and poor therapeutic response, including KRAS, BRAF, and NRAS, compared to individuals with late-onset disease (Table 1).